Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302

被引：0
|
作者：
Mainwaring, P. [1 ]
Yu, E. Y. [2 ]
Londhe, A. [3 ]
Van Poppel, H. [4 ]
Rathkopf, D. E. [5 ,6 ]
Smith, M. R. [7 ,8 ]
Souza, P. [9 ]
Griffin, T. W. [10 ]
Ryan, C. J. [11 ]
机构：
[1] Hematol & Oncol Clin Australia, Brisbane, Qld, Australia
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Janssen Res & Dev LLC, Raritan, NJ USA
[4] Katholieke Univ Leuven Hosp, Louvain, Belgium
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Harvard Univ, Sch Med, Boston, MA USA
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Univ Western Sydney, Sch Med, Sydney, NSW, Australia
[10] Janssen Res & Dev, Los Angeles, CA USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
41
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [11] Impact of Prior Local Trecepherapy (PLT) on survival in metastatic castration resistant prostate cancer (mCRPC). Results from COU-AA-302 trial
    Rodrigo Aliaga, M.
    Lorente Estelles, D.
    Garau Perello, C.
    Sanchez Llopis, A.
    Bosquet Sanz, M.
    Di Capua Sacoto, C.
    Villamon Fort, R.
    Blasco Maspons, J. A.
    Alonso Coscojuela, M.
    Sanchez Hernandez, A.
    EUROPEAN UROLOGY, 2021, 79 : S1206 - S1207
  • [12] Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results
    Morris, Michael J.
    Molina, Arturo
    Small, Eric J.
    de Bono, Johann S.
    Logothetis, Christopher J.
    Fizazi, Karim
    de Souza, Paul
    Kantoff, Philip W.
    Higano, Celestia S.
    Li, Jinhui
    Thian Kheoh
    Larson, Steven M.
    Matheny, Shannon L.
    Naini, Vahid
    Burzykowski, Tomasz
    Griffin, Thomas W.
    Scher, Howard I.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) : 1356 - +
  • [13] Effect of concomitant medication use on outcomes of ties and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
    Hamilton, Robert James
    Li, Jinhui
    Naini, Vahid
    San Kheoh, Thian
    De Porre, Peter
    Molina, Arturo
    Lelbowitz-Amit, Raya
    De Bono, Johann Sebastian
    Scher, Howard I.
    Ryan, Charles J.
    Chi, Kim N.
    Joshua, Anthony M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [14] Impact of Bone-targeted Therapies in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302
    Saad, Fred
    Shore, Neal
    Van Poppel, Hendrik
    Rathkopf, Dana E.
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher J.
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Griffin, Thomas A.
    De Porre, Peter
    Londhe, Anil
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    EUROPEAN UROLOGY, 2015, 68 (04) : 570 - 577
  • [15] Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302
    Cella, D.
    Traina, S.
    Li, T.
    Johnson, K.
    Ho, K. F.
    Molina, A.
    Shore, N. D.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 392 - 397
  • [16] Prognostic value of PSA progression in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the COU-AA-302 trial.
    Lorente, David
    Lozano, Rebeca
    de Velasco, Guillermo
    De Julian, Maria
    Rodrigo, Miguel
    Sanchez, Angel L.
    Di Capua, Carlos
    Castro, Elena
    Sanchez Hernandez, Alfredo
    Olmos, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [17] Application of abiraterone acetate (AA) in chemo-naive metastatic castration-resistant prostate cancer (mCRPC) patients who did not fulfil the patient inclusion criteria in the COU-AA-302 study
    Poon, Darren M. C.
    Kuen, Chan
    Lee, S. H.
    Chan, T. W.
    Sze, Chun-Kin
    Lee, Ka Chai
    Lam, Daisy
    Ting, Chan Fong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [18] Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)
    Rathkopf, Dana E.
    Smith, Matthew R.
    De Bono, Johann Sebastian
    Logothetis, Christopher
    Shore, Neal
    De Souza, Paul L.
    Fizazi, Karim
    Mulders, Peter
    Mainwaring, Paul N.
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott A.
    Fradet, Yves
    Griffin, Thomas W.
    Park, Youn Choi
    Kheoh, Thian San
    Small, Eric Jay
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [19] PREDICTORS OF RADIOGRAPHIC PROGRESSION IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE: RETROSPECTIVE ANALYSIS OF COU-AA-302
    Martin, Lisa
    Alibhai, Shabbir
    Komisarenko, Maria
    Timilshina, Narhari
    Finelli, Antonio
    JOURNAL OF UROLOGY, 2018, 199 (04): : E230 - E230
  • [20] Clinical versus radiographic progression and overall survival for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from COU-AA-302.
    Ryan, Charles J.
    Kheoh, Thian
    Scher, Howard I.
    De Porre, Peter
    Yu, Margaret K.
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345